InvestorsHub Logo
Followers 12
Posts 471
Boards Moderated 0
Alias Born 06/20/2020

Re: Minnesinger post# 363935

Tuesday, 06/29/2021 12:53:43 PM

Tuesday, June 29, 2021 12:53:43 PM

Post# of 403132
Very intriguing connecting of dots!

Here's another dot about the DOD and brilacidin in case others don’t already know. Polymedix received at least 15 research grants or contracts, including several from the Army, for research on “novel defensin-mimetic antimicrobial compounds” (PMX-30063, brilacidin, was their most promising compound). Perhaps this past research helped IPIX get interest on brilacidin as an antiviral? I'm unclear as to why IPIX wouldn't have issued a PR on gov't funding.

Here are a couple articles about Polymedix and DOD funding:
Radnor-based Polymedix earns $1.6 million contract to combat biowarfare pathogens
More Army funding for PolyMedix antimicrobial research

Here's a quote from a Polymedix 2012 press release: PolyMedix Reports Second Quarter 2012 Financial Results:

Defensin-mimetic Research

* PolyMedix recently received a grant from the National Institutes of Health for up to $3 million of funding to develop defensin-mimetic antimicrobial compounds against malaria. This second phase of grant funding follows a successful first phase in which PolyMedix previously received $1 million of funding for anti-malaria research. This work is being conducted in collaboration with Dr. Doron Greenbaum at the University of Pennsylvania.

Previously, PolyMedix has received 15 grants and sponsored research contracts, from the National Institutes of Health, the National Science Foundation, the Defense Threat Reduction Agency, the United States Army, and the United States Navy. PolyMedix continues to strive to support the majority of its research costs through such grant and research contract funding. With this support, PolyMedix has to date created a library of approximately 1,600 defensin-mimetic antimicrobial compounds in multiple distinct chemical series, which are being evaluated for potential use in indications such as malaria, Gram-negative pathogens, food-borne pathogens, fungal pathogens, and for biodefense applications.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News